Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to -$211.0 million.

  • Adma Biologics' Retained Earnings rose 4981.15% to -$211.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.0 million, marking a year-over-year increase of 4981.15%. This contributed to the annual value of -$308.6 million for FY2024, which is 3904.61% up from last year.
  • Latest data reveals that Adma Biologics reported Retained Earnings of -$211.0 million as of Q3 2025, which was up 4981.15% from -$247.5 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Retained Earnings ranged from a high of -$211.0 million in Q3 2025 and a low of -$506.3 million during Q4 2023
  • For the 5-year period, Adma Biologics' Retained Earnings averaged around -$408.5 million, with its median value being -$437.1 million (2022).
  • As far as peak fluctuations go, Adma Biologics' Retained Earnings tumbled by 2637.09% in 2021, and later skyrocketed by 4981.15% in 2025.
  • Adma Biologics' Retained Earnings (Quarter) stood at -$412.1 million in 2021, then fell by 15.99% to -$478.0 million in 2022, then decreased by 5.91% to -$506.3 million in 2023, then surged by 39.05% to -$308.6 million in 2024, then skyrocketed by 31.61% to -$211.0 million in 2025.
  • Its last three reported values are -$211.0 million in Q3 2025, -$247.5 million for Q2 2025, and -$281.7 million during Q1 2025.